Fear God (UNDER CONSTRUCTION)

FEAR GOD

Revelation 14: 7 And I saw another angel fly in the midst of heaven, having the everlasting gospel to preach unto them that dwell on the earth, and to every nation, and kindred, and tongue, and people, 7Saying with a loud voice, Fear God, and give glory to him; for the hour of his judgment is come: and worship him that made heaven, and earth, and the sea, and the fountains of waters. 8And there followed another angel, saying, Babylon is fallen, is fallen, that great city, because she made all nations drink of the wine of the wrath of her fornication. 8And there followed another angel, saying, Babylon is fallen, is fallen, that great city, because she made all nations drink of the wine of the wrath of her fornication. 9And the third angel followed them, saying with a loud voice, If any man worship the beast and his image, and receive his mark in his forehead, or in his hand, 10The same shall drink of the wine of the wrath of God, which is poured out without mixture into the cup of his indignation; and he shall be tormented with fire and brimstone in the presence of the holy angels, and in the presence of the Lamb: 11And the smoke of their torment ascendeth up for ever and ever: and they have no rest day nor night, who worship the beast and his image, and whosoever receiveth the mark of his name. 12Here is the patience of the saints: here are they that keep the commandments of God, and the faith of Jesus.

Ecclesiastes 12:13 Let us hear the conclusion of the whole matter: Fear God, and keep his commandments: for this is the whole duty of man.14For God shall bring every work into judgment, with every secret thing, whether it be good, or whether it be evil.

Universality and Cosmology

ANALYZING UNDERLYING IMPETUSES AS REFLECTED IN HISTORY (1840's-present)
Religion Civil Rights Science and Technology Space Forms of government Wars and conflicts
Crimes against humanity Literature Entertainment

Universitarianism reflected in religions, military, and politics. (1800's) III

Showing posts with label Murder. Show all posts
Showing posts with label Murder. Show all posts

Friday, October 15, 2010

Chicago Tylenol murders

Chicago Tylenol murders

From Wikipedia, the free encyclopedia
Jump to: navigation, search
The Chicago Tylenol murders occurred when seven people died after taking pain-relief capsules that had been poisoned. The Tylenol poisonings, code-named TYMURS by the FBI, took place in the autumn of 1982 in the Chicago area of the United States. These poisonings involved Extra-Strength Tylenol medicine capsules which had been laced with potassium cyanide.[1] The incident led to reforms in the packaging of over-the-counter substances and to federal anti-tampering laws. The case remains unsolved and no suspects have been charged. A $100,000 reward, offered by Johnson & Johnson for the capture and conviction of the "Tylenol Killer," has never been claimed.

Contents

[show]

[edit] The incidents

Wednesday morning, September 29, 1982, 12-year-old Mary Kellerman of Elk Grove Village, Illinois, died after taking a capsule of Extra Strength Tylenol. Adam Janus of Arlington Heights, Illinois, died in the hospital shortly thereafter. Adam's brother Stanley of Lisle, Illinois, and sister-in-law Theresa died after gathering to mourn his death, having taken pills from the same bottle. Soon afterward, Mary McFarland of Elmhurst, Paula Prince of Chicago, and Mary Reiner of Winfield, Illinois, also died in similar incidents.[2][3] Investigators soon discovered the Tylenol link. Urgent warnings were broadcast, and police drove through Chicago neighborhoods issuing warnings over loudspeakers.
As the tampered bottles came from different factories, and the seven deaths had all occurred in the Chicago area, the possibility of sabotage during production was ruled out. Instead, the culprit was believed to have entered various supermarkets and drug stores over a period of weeks, pilfered packages of Tylenol from the shelves, adulterated their contents with solid cyanide compound at another location, and then replaced the bottles. In addition to the five bottles which led to the victims' deaths, three other tampered bottles were discovered.
Johnson & Johnson, the parent company of McNeil, distributed warnings to hospitals and distributors and halted Tylenol production and advertising. On October 5, 1982, it issued a nationwide recall of Tylenol products; an estimated 31 million bottles were in circulation, with a retail value of over US$100 million. The company also advertised in the national media for individuals not to consume any products that contained acetaminophen. When it was determined that only capsules were tampered with, they offered to exchange all Tylenol capsules already purchased by the public with solid tablets.

[edit] Suspects

During the initial investigations, a man named James W. Lewis sent a letter to Johnson & Johnson demanding $1 million to stop the cyanide-induced murders. Police were unable to link him with the crimes, as he and his wife were living in New York City at the time. He was convicted of extortion, served 13 years of a 20-year sentence, and was released in 1995 on parole. WCVB Channel 5 of Boston reported that court documents, released in early 2009, "show Department of Justice investigators concluded suspect James W. Lewis, who now lives in Cambridge, Massachusetts, was responsible for the poisonings, despite the fact that they did not have enough evidence to charge him." Lewis continues to deny responsibility for the poisonings.[4][5]
A second man, Roger Arnold, was investigated and cleared of the killings; however, the media attention caused him to have a nervous breakdown, and he blamed a bar owner, Marty Sinclair, for the police investigation of him. In the summer of 1983, he shot and killed John Stanisha, whom he mistook for Sinclair, but who was, in fact, an innocent man who did not know Arnold.[6] Arnold was convicted in January 1984 and served 15 years of a 30-year sentence for second degree murder. He died in June 2008.
Laurie Dann, who poisoned and shot victims in a May 1988 rampage in and around Winnetka, Illinois, was briefly considered as a suspect, but no direct connection was found.[7]

[edit] Aftermath

The media gave Johnson & Johnson much positive coverage for its handling of the crisis; for example, an article in the Washington Post said, "Johnson & Johnson has effectively demonstrated how a major business ought to handle a disaster." The article further stated that "this is no Three Mile Island accident in which the company's response did more damage than the original incident," and applauded the company for being honest with the public. In addition to issuing the recall, Johnson & Johnson established relations with the Chicago Police, the FBI, and the Food and Drug Administration. This way the company could have a part in searching for the person who laced the Tylenol capsules and they could help prevent further tamperings.[8]analgesic in the US. While at the time of the scare the market share of Tylenol collapsed from 35% to 8%, it rebounded in less than a year, a move credited to J&J's prompt and aggressive reaction. In November, it reintroduced capsules but in a new, triple-sealed package, coupled with heavy price promotions and within several years, Tylenol had become the most popular over-the-counter
A number of copycat attacks involving Tylenol and other products (see Stella Nickell for information on the 1986 Excedrin tampering murders) ensued during the following years. One of these incidents occurred in the Chicago area; unlike Tylenol, it actually forced the end of the product affected by the hoax, Encaprin, from Procter & Gamble. However, the incident did inspire the pharmaceutical, food, and consumer product industries to develop tamper-resistant packaging, such as induction seals and improved quality control methods. Moreover, product tampering was made a federal crime.
Additionally, the tragedy prompted the pharmaceutical industry to move away from capsules, which were easy to contaminate as a foreign substance could be placed inside without obvious signs of tampering. Within the year, the Food and Drug Administration introduced more stringent regulations to avoid product tampering. This led to the eventual replacement of the capsule with the solid "caplet", a tablet made in the shape of a capsule, as a drug delivery form and with the addition of tamper-evident safety-seals to bottles of many sorts.

[edit] Ongoing investigations

In early January 2009, Illinois authorities renewed the investigation. Federal agents searched the home of Lewis in Cambridge, Massachusetts, and seized a number of items.[9] In Chicago, an FBI spokesman declined to comment but said "we'll have something to release later possibly."[10] Law enforcement officials have received a number of tips related to the case coinciding with its anniversary. In a written statement,[11] the FBI explained,
This review was prompted, in part, by the recent 25th anniversary of this crime and the resulting publicity. Further, given the many recent advances in forensic technology, it was only natural that a second look be taken at the case and recovered evidence.
In January 2010, both Lewis and his wife submitted DNA samples and fingerprints to authorities.[5] Lewis stated "if the FBI plays it fair, I have nothing to worry about."[5]

Seroquel

Quetiapine

From Wikipedia, the free encyclopedia
  (Redirected from Seroquel)
Jump to: navigation, search
Quetiapine
Systematic (IUPAC) name
2-(2-(4-dibenzo[b,f][1,4]thiazepine- 11-yl- 1-piperazinyl)ethoxy)ethanol
Identifiers
CAS number 111974-69-7
ATC code N05AH04
PubChem CID 5002
IUPHAR ligand ID 50
DrugBank DB01224
ChemSpider 4827
Chemical data
Formula C21H25N3O2S 
Mol. mass 383.5099 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability 9%
Metabolism Hepatic
Half-life 6 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat. C(US)
Legal status -only (US)
Routes Oral
 Yes(what is this?)  (verify)Y
Quetiapine (pronounced /kwɨˈtaɪ.əpiːn/ kwi-TYE-ə-peen), marketed by AstraZeneca as Seroquel and by Orion Pharma as Ketipinor, both as a quetiapine fumarate salt of the drug, is an atypical antipsychoticschizophrenia, bipolar I mania, bipolar II depression, bipolar I depression, and used off-label for a variety of other purposes, including insomnia and anxiety disorders. used in the treatment of
Annual sales are approximately $4.7 billion worldwide, and $2.9 billion in the U.S.[1] The patent in the U.S., which was set to expire in 2011, received a pediatric exclusivity extension, which pushed its expiration to March 26, 2012.[2] The patent already expired in Canada. Several pharmaceutical companies are now making generic versions of quetiapine. Quepin is a generic version manufactured and marketed by Specifar ABEE, Athens, Greece.[3]
Controversy arose over AstraZeneca's aggressive marketing of the Seroquel for off-label uses, including treatment of PTSD in veterans. Several American soldiers and veterans have died while taking Seroquel.[4]

Contents

[show]

[edit] Uses

Quetiapine (Seroquel) 25 mg tablets, next to US one-cent coin for comparison.
Quetiapine is indicated for the treatment of schizophrenia, depressive episodes associated with bipolar disorder, acute manic episodes associated with bipolar I disorder (as either monotherapy or adjunct therapy to lithium or valproate), and maintenance treatment of bipolar I disorder (as adjunct therapy to lithium or divalproex). Quetiapine received its initial indication from the U.S. Food and Drug Administration for treatment of schizophrenia in 1997.[5] In 2004, it received its second indication for the treatment of mania-associated bipolar disorder.[6] It is sometimes used off-label, often as an augmentation agent, to treat conditions such as obsessive-compulsive disorder, post-traumatic stress disorder, restless legs syndrome, autism, alcoholism, depression,[7] Tourette syndrome,[8] and has been used by physicians as a sedative for those with sleep disorders or anxiety disorders.[9]
In 2005, the National Institute of Mental Health examined quetiapine and other antipsychotics to uncover the comparative efficacy of "second generation" anti-psychotics against older anti-psychotics (known as "first generation" or "typical anti-psychotics"). Such information could be important to the patients, as the newer drugs are far more expensive than their older counterparts. Published in the New England Journal of Medicine, the results of the CATIE ("clinical antipsychotic trials of interventional effectiveness") trial were somewhat mixed. 74% of trial participants (of the 1,493 people who were in different treatment groups) discontinued before the trial ended. The majority of the participants discontinued treatment due to intolerable side effects or lack of efficacy. Olanzapine (Zyprexa) was considered the most effective in terms of the time it took patients to drop out of the study, although it was associated with greater weight gain and glucoseperphenazine.[10] The CATIE trial was supported by a grant (N01 MH90001) from the NIMH and by the Foundation of Hope of Raleigh, N.C. The individual pharmaceutical companies, whose drugs were used, donated all of the study medication. intolerability found in diabetes patients. The effects of all other treatments (such as Seroquel) were considered to be similar to the effects of the generic (and dramatically less expensive) drug,
A report in British Medical Journal in 2005 showed that quetiapine was ineffective in reducing agitation among Alzheimer's patients, whose usage of the drug constituted 29% of sales. In fact, quetiapine was found to worsen cognitive functioning in elderly patients with dementia.[11]
Use of quetiapine to minimize the symptoms of opioid withdrawal has been studied.[12]

[edit] Investigations

In 2007 and 2008, studies were conducted on quetiapine’s efficacy in treating generalized anxiety disorder and major depression. In April 2009, the Psychopharmacologic Drugs Advisory Committee of the US Food and Drug Administration (FDA) held a public meeting to discuss whether study results supported the FDA's approval for anxiety and depression, with risks of metabolic side effects and of tardive dyskinesia and sudden cardiac death.[13]

In 2010 AstraZeneca was ordered to pay $520 million in a settlement with State and Federal authorities. According to the settlement AstraZeneca promoted the sale and use of Seroquel for uses not approved by the FDA, and paid illegal kickbacks to doctors. As a result of their promotional activity, physicians prescribed Seroquel for children, adolescents and dementia patients in long term care facilities.[14]

[edit] Pharmacology

Quetiapine has the following pharmacological actions:[15][16][17][18]
This means Quetiapine is dopamine, serotonin and adrenergic antagonist, anticholinergic substance and antihistamine. Quetiapine binds strongly to serotonin receptors. Serial PET scans evaluating the D2 receptor occupancy of quetiapine have demonstrated that quetiapine very rapidly disassociates from the D2[19] Theoretically, this allows for normal physiological surges of dopamine to elicit normal effects in areas such as the nigrostriatal and tuberoinfundibular pathways, thus minimizing the risk of side effects such as pseudo-parkinsonism as well as elevations in prolactin.[citation needed] receptor.

Zyprexa (? + rex(king))

Olanzapine

From Wikipedia, the free encyclopedia
  (Redirected from Zyprexa)
Jump to: navigation, search
Olanzapine
Systematic (IUPAC) name
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
Identifiers
CAS number 132539-06-1
ATC code N05AH03
PubChem CID 4585
IUPHAR ligand ID 47
DrugBank DB00334
ChemSpider 10442212
Chemical data
Formula C17H20N4S 
Mol. mass 312.439
SMILES eMolecules & PubChem
Physical data
Melt. point 195 °C (383 °F)
Solubility in water Practically insoluble in water mg/mL (20 °C)
Pharmacokinetic data
Bioavailability 87% [1]
Metabolism Hepatic (direct glucuronidation and CYP mediated oxidation)
Half-life 21–54 hours
Excretion urine 57%, feces 30%
Therapeutic considerations
Pregnancy cat. C
Legal status Prescription only
Routes oral, intramuscular
 Yes(what is this?)  (verify)Y

Zyprexa 10 mg tablets (AU)
Olanzapine (trade names Zyprexa, Zalasta, Zolafren, Olzapin, Oferta, Zypadhera or in combination with fluoxetine Symbyax) is an atypical antipsychotic, approved by the FDA for the treatment of schizophrenia and bipolar disorder.[2] Olanzapine is structurally similar to clozapine, but is classified as a thienobenzodiazepine. The olanzapine formulations are manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper expires in 2011 (in October 2009 a Canadian judge ruled that the 1991 patent was invalid).[3] Sales of Zyprexa in 2008 were $2.2B in the US alone, and $4.7B in total.[4]

Contents

[show]

[edit] Indications and Usage

  • oral formulation: acute and maintenance treatment of schizophrenia in adults, acute treatment of manic or mixed episodes associated with bipolar I disorder (monotherapy and in combination with lithium or valproate)
  • intramuscular formulation: acute agitation associated with schizophrenia and bipolar I mania in adults
  • oral formulation combined with fluoxetine: treatment of acute depressive episodes associated with bipolar I disorder in adults, or treatment of acute, resistant depression in adults [5]
Known FDA approvals are as follows:
  • approved for the treatment of the manifestations of psychotic disorders on September 6, 1996[6]
  • approved in combination with fluoxetine for the treatment of depressive episodes associated with Bipolar disorder on December 24, 2003[7]
  • approved for the long-term treatment of bipolar I disorder on January 14, 2004[8]
  • approved in combination with fluoxetine for treatment of resistant depression on March 19, 2009.[9]

[edit] Off-label uses

Case-reports, open-label, and small pilot studies suggest efficacy of olanzapine for the treatment of some anxiety spectrum disorders (e.g. generalized anxiety disorder,[10] panic disorder,[11] post-traumatic stress disorder);[12] however, olanzapine has not been rigorously evaluated in randomized, placebo-controlled trials for this use and is not FDA approved for these indications. Other common off-label uses of olanzapine include the treatment of eating disorders (e.g. anorexia nervosa) and as an adjunctive treatment for major depressive disorder without psychotic features. It has also been used for Tourette syndrome and stuttering.[13][14] Olanzapine is also used in many addiction clinics as a sleep aid (usually 2.5–5 mg) due to its low abuse profile and zero addictive properties.

[edit] Prevention of psychosis

Olanzapine has been considered as part of an early psychosis approach for schizophrenia. The Prevention through Risk Identification, Management, and Education (PRIME) study, funded by the National Institute of Mental Health and Eli Lilly, tested the hypothesis that olanzapine might prevent the onset of psychosis in people at very high risk for schizophrenia. The study examined 60 patients with prodromal schizophrenia, who were at an estimated risk of 36–54% of developing schizophrenia within a year, and treated half with olanzapine and half with placebo.[15] In this study, patients receiving olanzapine had a lower risk of progressing to psychosis, although the difference did not reach statistical significance. Olanzapine was effective for treating the prodromal symptoms, but was associated with significant weight gain.[16]

[edit] Use in elderly

Citing an increased risk of stroke, in 2004 the Committee on the Safety of Medicines (CSM) in the UK issued a warning that olanzapine and risperidone, both atypical antipsychotic medications, should not be given to elderly patients with dementia. In the U.S., olanzapine comes with a black box warning for increased risk of death in elderly patients. It is not approved for use in patients with dementia-related psychosis.[17][18]
However, a BBC investigation in June 2008 found that this advice was being widely ignored by British doctors.

Risperdal (psedoscience and the psychiatric equivalent to AIDS/HIV/H4)

Risperidone

From Wikipedia, the free encyclopedia
  (Redirected from Risperdal)
Jump to: navigation, search
Risperidone
Systematic (IUPAC) name
4-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-
1-piperidyl]ethyl]-3-methyl-
2,6-diazabicyclo[4.4.0]deca-1,3-dien-5-one
Identifiers
CAS number 106266-06-2
ATC code N05AX08
PubChem CID 5073
IUPHAR ligand ID 96
DrugBank DB00734
ChemSpider 4895
Chemical data
Formula C23H27FN4O2 
Mol. mass 410.485 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability 70% (oral)
Metabolism Hepatic (CYP2D6-mediated)
Half-life 3–20 hours
Excretion Urinary
Therapeutic considerations
Pregnancy cat. C
Legal status Prescription only
Routes Oral and extended-release intramuscular injection
 Yes(what is this?)  (verify)Y
Risperidone (pronounced Ris-PEAR-rǐ-dōne) is an atypical antipsychotic used to treat schizophreniaschizoaffective disorder, the mixed and manic states associated with bipolar disorder, and irritability in children with autism. The drug was developed by Janssen-Cilag and first released in 1994[1]. It is sold under the trade name Risperdal in the Netherlands, United States, Canada, Australia, United Kingdom, Portugal, Spain, Turkey, New Zealand and several other countries, Risperdal or Ridal in New Zealand, Sizodon or Riscalin in India, Rispolept in Eastern Europe, and Russia, and Belivon, or Rispen elsewhere. (including adolescent schizophrenia),

Contents

[show]

[edit] Indications and Uses

  • treatment of schizophrenia in adults
  • treatment of schizophrenia in adolescents aged 13-17 years
  • alone or in combination with lithium or valproate, for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults
  • alone in the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in children and adolescents aged 10-17 years
  • treatment of irritability associated with autistic disorder in children and young adults
  • it has also been used as a control drug for people with tourette syndrome and other tic disorders.
  • treatment of major depression with psychotic features
  • cure persistent or intractable hiccups[2]
Risperidone was approved by the United States Food and Drug Administration (FDA) in 1993 for the treatment of schizophrenia.[3]
On August 22, 2007, risperidone was approved as the only drug agent available for treatment of schizophrenia in youth ages 13–17; it was also approved that same day for treatment of bipolar disorder in youth and children ages 10–17, joining lithium. Risperidone contains the functional groups of benzisoxazolepiperidine as part of its molecular structure. In 2003 the FDA approved risperidone for the short-term treatment of the mixed and manic states associated with bipolar disorder. In 2006 the FDA approved risperidone for the treatment of irritability in children and adolescents with autism.[4] The FDA's decision was based in part on a study of autistic children with severe and enduring problems of violent meltdowns, aggression, and self-injury; risperidone is not recommended for autistic children with mild aggression and explosive behavior without an enduring pattern.[5] Like other atypical antipsychotics, risperidone has also been used off-label for the treatment of anxiety disorders, such as obsessive-compulsive disorder; severe, treatment-resistant depression with or without psychotic features; tourette syndrome; disruptive behavior disorders in children; and eating disorders, among others. In two small studies risperidone was reported to successfully treat the symptoms of phencyclidine (PCP) psychosis due to acute intoxication[6] and chronic use.[7] and
A 2009 Cochrane Library review found no evidence from randomized controlled trials that risperidone is effective for the treatment of attention-deficit hyperactivity disorder (ADHD) in people with intellectual disabilities.[8] A multi-year UK study by the Alzheimer's Research Trust suggested that this and other neuroleptic anti-psychotic drugs commonly given to Alzheimer's patients with mild behavioural problems often made their condition worse. The study concluded that:
For most patients with AD, withdrawal of neuroleptics had no overall detrimental effect on functional and cognitive status and by some measures improved functional and cognitive status. Neuroleptics may have some value in the maintenance treatment of more severe neuropsychiatric symptoms, but this possibility must be weighed against the unwanted effects of therapy.[9]

[edit] Availability


Risperdal 4 mg tablets (UK)
Janssen's patent on Risperdal expired on December 29, 2003, opening the market for cheaper generic versions of the drug from other companies, and Janssen's exclusive marketing rights expired on June 29, 2004 (the result of a pediatric extension.)
Risperidone is available as a tablet in 0.25, 0.5, 1, 2, 3 and 4 mg sizes, as an oral solution (30ml, 1 mg/ml), and as a 12.5 mg, 25 mg, 37.5 mg and 50 mg ampoule Risperdal Consta, which is a depot injectionRisperdal M-Tabs and elsewhere as Risperdal Quicklets. administered once every two weeks. It is also available as a wafer known in the United States and Canada as
Risperidone became available as a generic drug in October 2008 from Teva Pharmaceuticals, Dr. Reddy's Laboratories, Inc. and Patriot Pharmaceutics. The Patriot generic is Janssen Pharmaceutical's "authorized generic pharmaceutical."

[edit] Side effects

Risperidone has been associated with weight gain.[10] Other common side effects include akathisia, sedation, dysphoria, insomnia, sexual dysfunction, low blood pressure, high blood pressure, muscle stiffness, muscletremors, increased salivation, constipation, and stuffy nose. pain,
Many antipsychotics are known to cause hyperprolactinemia which may lead to hypogonadism-induced osteoporosis, galactorrhoea, gynaecomastia, irregular menstruation and sexual dysfunction. However, risperidone is known to increase prolactin to a greater extent than other atypical antipsychotics. Although lactation is possible in both sexes using other antipsychotic drugs, risperidone is the biggest offender.[11][12][13] It is thought that once risperidone raises prolactin, it may cause prolactinoma, a benign tumor of the pituitary gland. Tumors, in general, are not considered reversible. Medical therapy may help reduce tumor size and restore normal reproduction and pituitary function, however, dopamine agonists[14] There is a higher association between pituitary neoplasms with use of risperidone and amisulpride than with other antipsychotic agents. are not likely to be prescribed to antipsychotic users, thus, surgery or radiation treatment may be required. This condition may recur if the patient is switched to a different antipsychotic. Risperidone has been known to cause increased thoughts of suicide.
Risperidone can potentially cause tardive dyskinesia (TD),[15] extrapyramidal symptoms (EPS),[15] and neuroleptic malignant syndrome (NMS).[15] Risperidone may also trigger diabetes and more serious conditions of glucose metabolism, including ketoacidosis and hyperosmolar coma, according to an FDA Warning Letter issued to Janssen Pharmaceutica, Inc. on 19-Apr-04.[16]

[edit] Pharmacology

This drug belongs to a class of antipsychotic drugs known as atypical antipsychotics that have more pronounced serotonin antagonism than dopamine antagonism, but risperidone is unique in this class because it retains dopamine antagonism. It has high affinity for D2 dopaminergic receptors. It has actions at several 5-HT (serotonin) receptor subtypes. These are 5-HT2C, linked to weight gain, 5-HT2A,linked to its antipsychotic action and relief of some of the extrapyramidal side effects (EPS) experienced with the typical neuroleptics.
It reaches peak plasma levels quickly regardless of whether it is administered as a liquid or pill. Risperidone is metabolised fairly quickly, so the potential for nausea subsides usually in two to three hours. However, the active metabolite, 9-hydroxy-risperidone, which has similar pharmacodynamics to risperidone, remains in the body for much longer, and has been developed as an antipsychotic in its own right, called paliperidone.
An intramuscular preparation, marketed as Risperdal Consta, can be given once every two weeks. It is slowly released from the injection site. This method of administration may be used on sanctioned patients who are declining, or consenting patients who may have disorganized thinking and cannot remember to take their daily doses.[17] Doses range from 12.5 to 50 mg given as an intramuscular injection once every two weeks.

By Years

1833 (1) 1836 (1) 1844 (11) 1848 (3) 1850 (2) 1862 (1) 1863 (1) 1866 (1) 1867 (1) 1898 (1) 1932 (2) 1935 (1) 1938 (3) 1939 (1) 1947 (2) 1950 (1) 1958 (1) 1960 (1) 1961 (1) 1962 (1) 1964 (6) 1965 (1) 1966 (2) 1967 (2) 1968 (1) 1969 (1) 1972 (1) 1973 (1) 1976 (1) 1977 (3) 1978 (2) 1979 (15) 1980 (2) 1981 (9) 1982 (3) 1984 (1) 1986 (1) 1989 (6) 1990 (17) 1991 (10) 1992 (4) 1993 (15) 1994 (4) 1997 (2) 1999 (3) 2001 (3) 2002 (4) 2003 (2)

Search This Blog